Background: Bisphenol A is an endocrine disrupting chemical associated with type
| INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver illness in Western countries, since its prevalence is estimated to be 20%-30% in general population. 1 NAFLD can range from simple lipid accumulation in hepatocytes (NAFL) to steatohepatitis (NASH). Therefore, NAFLD is a pathology that may evolve in fibrosis, cirrhosis and hepatocellular carcinoma (HCC). [2] [3] [4] [5] NAFLD can be associated with obesity and features of the metabolic syndrome such as hypertension, dyslipidemia, central adiposity, insulin resistance or type 2 diabetes mellitus. 6, 7 Moreover, given the epidemic spread of such conditions, the epidemiological impact of this pathology could grow in the next future and for this reason the screening for NAFLD in specific categories of population could be useful to reduce the impact of this disease on the human health. 8, 9 In this regard, the understanding of the mechanisms underlying the development and progression of NAFLD is still an open challenge.
The availability of cheap and hypercaloric food is certainly responsible for growing incidence of this pathology in western countries, however, the importance of substances contained in food packages and the large distribution of this chemicals in the environment is a non well-explored topic that could have a relevant role in the era of metabolic liver disease. In this regard, relevant interest has been addressed endocrine disrupting chemicals, a heterogenic group of chemicals, which can be found in food packages or insecticide residues on vegetable crops, and to which many people are exposed. 10 The peculiar characteristic of this substance is the capacity to interfere and alter mechanism and function of endocrine system, in particular sex hormone activity and thyroid. 11 Of notice, it has been reported that in the populations with higher rates of obesity or type 2 diabetes mellitus there is a greater exposure to endocrine disrupting chemicals such as p,p 0 -dichlorodiphenyltrichloroethane and dioxins. 12, 13 Bisphenol A is a well-known endocrine disrupter and a building block of polycarbonate plastics often used in food and beverage containers and as an additive in other plastics. Bisphenol A is also a component of epoxy resins used in some dental materials and for the lining of food and beverage containers. 14 Additional uses for bisphenol A include items of everyday life, as compact disc and digital versatile disc coating, electronic equipment, cars, recycled paper and carbonless paper often used in register receipts. Bisphenol A is one of the highest volume chemicals produced worldwide, and human exposure to bisphenol A is thought to be ubiquitous. 15 Bisphenol A exposure has been associated epidemiologically with type 2 diabetes mellitus, cardiovascular disease and liver enzyme abnormalities. 12 In this regard, several studies supported the concept that bisphenol A exposure disrupts pancreatic b-cells function and the whole-body blood glucose homoeostasis. Bisphenol A has been reported to induce an increase in insulin content in isolated islets compared with vehicle-exposed islets. 16, 17 These effects are probably due to ability of BPA to favour insulin synthesis through an uncommon oestrogendependent pathway involving phosphorylation of Erk-1 and 2 and then supporting the onset of tissue insulin resistance. 18 Notably, Wei et al demonstrated the relationship between foetal and neonatal exposure to bisphenol A and metabolic illnesses such as obesity, insulin resistance and glucose intolerance in rat offspring fed with both normal and high-fat diet. 19 The exposure to bisphenol A has also been related to the modulation of genes involved in lipid synthesis, increased body weight, lipid accumulation and insulin secretion in mice. 20 Moreover, other studies reported a significant association between high urinary bisphenol A levels and disorders such as type 2 diabetes mellitus and obesity in a population-based sample of US adults, independent of potential confounding factors (smoking, alcohol consumption, serum cholesterol levels), gender and race/ethnicity. 12, 21 Finally, it has also been reported that bisphenol A in high doses may reduce the release of adiponectin from adipose tissue, the oxidation of fatty acids in muscles and the liver control in glucose production. 22 Given the previous evidence, it may be of high interest to investigate, both in clinical and in vitro study, the possible role of bisphenol A as a factor in the promotion of NAFLD. The aims of this current study were:
• To establish if bisphenol A plasmatic/urinary levels are higher in NAFLD patients than in healthy subjects. Therefore, we evaluated bisphenol A plasmatic and urinary levels in 60 patients with histological diagnosis of NAFL/NASH, with or without type 2 diabetes mellitus and/or metabolic syndrome compared to the same number of controls.
• To evaluate a correspondence between bisphenol A plasmatic/ urinary levels and the severity of liver disease.
• To observe any changes at the concentration of this contaminant resulting from bisphenol A-free diet for one month.
• To analyse, in vitro, on human liver cell line (HepG2) cells, the growth at high and at low glucose concentrations and the effect on oxidative stress resulted from exposure to bisphenol A at different concentrations as well as the capability to induce cell proliferation. of NAFLD, the aetiology and the staging of the disease were diagnosed after the exclusion of other causes of liver diseases, by serological tests and clinical data and by performing a liver biopsy.
| MATERIALS AND METHODS
Medical history, alcohol consumption, drug intake, current drug treatments, smoking habits, blood pressure, body mass index (BMI) and waist-to-height ratio (WHtR) were investigated. Additional data included routine laboratory tests (blood glucose and insulin, total cholesterol, high density lipoprotein, triglycerides, aspartate and alanine aminotransferases, gamma-glutamyltranspeptidase, blood count), and were obtained by blood peripheral venous samples.
We evaluated the following markers of oxidative stress in patients' sera before and after the bisphenol A-free diet: (1) Thiobarbituric acid reactive substances (TBARS). 23 The assay was performed Blood and urine samples were also collected to properly evaluate plasma and urine concentration of bisphenol A in NAFLD patients compared to healthy subjects.
Urine was collected in appropriate bisphenol A-free glass containers, the subjects collect 24 h urine and the bisphenol A concentration was corrected for creatinine values. The amount of plasma used for the analyses was 2, 5 mL and the amount of urine was 3 mL collected by the 24 hours collection of urine. We also evaluated the rate of excretion of bisphenol A using this formula: amount per ml of bisphenol A in 24 hours urine x total 24 hours urine volume/24. We expressed the results as mean AE SD and compared the values before and after bisphenol A-free diet.
Furthermore, we observed any changes in bisphenol A levels resulting from following a bisphenol A-free diet ( Figure 1 ) for at least a month. In all subjects, food intake was evaluated by electronic pro- 25 Alcohol use was evaluated with a standardised pre-codified questionnaire (complete AUDIT test). 26 The quantity of daily alcohol intake was calculated on the basis on a "drink" that corresponds to about 12 g of pure ethanol. 27 Body composition was evaluated by bioimpedance analysis (BIA 101S).
To obtain plasma without cells, anticoagulated blood, 
| Cell proliferation assay and TBARS assay
HepG2 was used to investigate on oxidative stress by bisphenol A exposure. 30 The 3 | RESULTS
| Clinical study
On the basis of the purposes of this study, 60 patients who showed our inclusion criteria and 60 age and sex-matched healthy subjects were enrolled. Demographical characteristics of our study population are reported in On the other hand, bisphenol A urinary levels were lower in NASH patients compared to NAFL ones, although this difference was not statistically significant between the two groups (4.36 AE 1.05 ng/mL vs 6.83 AE 1.06 ng/mL respectively; P = 0.201) ( Figure 3B ). All NAFLD patients followed a bisphenol A-free diet (Table 2) .
NAFLD patients showed higher TBARS values compared to controls (P < 0.01). Moreover, NASH patient showed higher TBARS levels in comparison to NAFL ones but this results was not statistically significant (P = 0.104). Superoxide dismutase and catalase activities were greater in NAFLD group then controls (P < 0.01) but the difference between NAFL group and NASH ones was not statistically significant (P = 0.081). After 1 month of bisphenol A-free diet NAFLD patients showed a reduction in TBARS levels, superoxide dismutase and catalase activities in comparison to T 0 but in a not statistically significant manner.
In relation to the nutritional assessment, we observed the same qualitative composition of diet between NAFLD group and controls in terms of percentage of macronutrients and micronutrients. In contrast, an important difference in terms of quantitative assessment of diet about caloric intake was observed: it was higher in NAFLD patients in comparison to controls (data not shown). There was no significant daily alcohol intake neither for NAFLD patients nor controls. Moreover, there was not any change in the quantitative/qualitative diet composition of NAFLD patients during and after bisphenol A-free diet. This dietary regimen was only focused to avoid food packages containing high level of BPA such as plastic containers with symbols "3 and 7" on the surface. These results show that bisphenol A increases proliferation rate only in high glucose concentration cells.
| In vitro study: bisphenol A effects on oxidative stress and intracellular lipid accumulation
Several environmental contaminants, including endocrine disrupting chemicals, can carry out their toxic effects through the oxidative stress mechanism and induction of lipoperoxidation. To evaluate the pro-oxidant action of bisphenol A on our HepG2 cells system, oxidative stress was assessed by TBARS assay (Figure 8) . In H-HepG2 cells at 48 h, bisphenol A led to an increase F I G U R E 3 Bisphenol A urine (A) and plasma (B) levels in steatosis (NAFL) (30) and steatohepatitis (NASH) patients (30) (*P < 0.0001 vs Controls, P = 0.041). Bisphenol A plasma levels appeared to be significantly higher in NASH patients compared to NAFL ones (7.79 AE 2.34 ng/mL vs 4.40 AE 0.57 ng/mL respectively; P = 0.041), independently from the presence of type 2 diabetes mellitus. On the other hand, bisphenol A urinary levels were lower in NASH patients compared to NAFL ones, although this difference was not statistically significant between the two groups (4.36 AE 1.05 ng/mL vs 6.83 AE 1.06 ng/mL respectively; P = 0.201)
in the levels of TBARS compared to untreated cells (P < 0.0001).
This evidence highlights its ability to induce oxidative stress and lipoperoxidation. F I G U R E 5 Bisphenol A plasma (A) and urine (B) levels of nonalcoholic fatty liver disease patients before and after bisphenol Afree diet for 1 month. There was a significant reduction in bisphenol A circulating levels between first and second check (5.30 AE 0.78 ng/ mL vs 2.02 AE 0.58 ng/mL respectively; P = 0.016). The reduction in bisphenol A urinary levels after bisphenol A-free diet was not statistically significant (6.17 AE 0.85 ng/mL vs 5.83 AE 0.65 ng/mL respectively; P = 0.221) The routine laboratory tests did not change in a statistically significant manner after 1 month of bisphenol A-free diet in non-alcoholic fatty liver disease patients group (P > 0.05).
to induce lipid cell accumulation and mitochondrial alterations associated with reactive oxygen species production and pro-inflammatory cytokine release in the liver. 37 Other studies have shown a possible link between bisphenol A exposure and the development and progression of NAFLD, even though these studies have only been carried out on cells in vitro or on mice. 18, 19, 38 In the light of these considerations, our results have provided some important insights: first of all, bisphenol A plasmatic and urinary levels showed a statistically significant increase in NAFLD patients compared to controls. This evidence focuses the attention on the fact that NAFLD patients show a major exposition to bisphe- In accordance with scientific literature regional anthropometric measures are associated with severity of NAFLD: age and waist circumference seem to be associated with liver fibrosis and simple anthropometric measurements of peripheral fat deposits may help stratify significant liver injury risk. 39 After ingestion, bisphenol A is metabolised in the liver in its inactive form, bisphenol A-G and excreted in urine, with a half-life ranging from 4 to 43 hours. 28 Nevertheless, bisphenol A has been found in adipose tissue, suggesting that its bio-accumulation occurs in lipids and other physiological compartments due to its lipoaffinity. 16 Bisphenol A release from adipose tissue may represent a source of continuous exposure for target organs, submitting them to a high possibility to develop a bisphenol A-induced damage. This statement leads to consider bisphenol A urinary levels as an esteem of daily intake levels, while circulating ones reflect the real exposure of target organs, that is, dependent from both the absorptions through all exposure pathways and the transformation from bisphenol A-G to bisphenol A at tissue level. 40 In accordance with literature, bisphenol A urinary levels of our patients and controls were higher than circulating ones even if this difference reached the statistical significance only in control. Indeed, most of bisphenol A is excreted in urine, due to the relatively rapid metabolism and excretion pathway. [41] [42] [43] [44] Our data show a more marked increase in circulating levels in NASH patients, compared to those with NAFL. Furthermore, there was a statistically significant association between bisphenol A plasma levels and the histological picture of inflammation according to the evaluation of lobular inflammation and ballooning.
As previous said, in our study, population high bisphenol A plasma concentration is probably due to the major accumulation and release from its adipose tissue reservoir because of high percentage of body fat in NASH group. Moreover this observation, according to literature showing drug metabolism alterations in NAFLD patients, and more specifically in NASH, may suggest an altered hepatic metabolism of endocrine disrupting chemicals in NASH patients. 45 This also agrees with a study showing an impaired metabolism of bisphenol A in human and mice liver disease, although this assumption requires further studies. 46 Another important finding of our research is that bisphenol A plasmatic levels showed a statistically significant decrease in patients after following the bisphenol A-free diet. This evidence demonstrated that bisphenol A is a potentially eradicable environmental factor simply following a bisphenol A-free diet. On the other hand, urinary level increase, although present, was not statistically significant, particularly in NASH patients. This phenomenon could be due to the fact that the main excretion way of bisphenol A is the urinary emunctory, bisphenol A levels was elevated also after Moreover, bisphenol A is excreted by urinary emunctory after a bisphenol A-free diet for a month, confirming the possibility to eliminate it completely, although it could be necessary a longer bisphenol A-free diet to remove the quantity stocked in adipose reservoir.
Thanks to the results of this paper, we discovered that 1 month with bisphenol A-free diet is not sufficient to eliminate bisphenol A accumulation completely.
Moreover bisphenol A-free diet for 1 month was not related in statistically significant manner with reduction in BMI. However to produce strong scientific evidences in this field, probably it is necessary to prolong the bisphenol A-free diet period more than one month. In this respect, we explained the possible theory that bisphenol A could be an environmental factor able to determine a worsening of NAFLD, especially along with obesity and diabetes.
By an analysis conducted during our experiment, we discovered that obese patients (without biopsy proven NAFLD) have high serum and urine levels of bisphenol A (data not shown) confirming that obese eat differently in comparison to lean subjects, however, the plasma and urine level of bisphenol A was directly correlated with fat percentage evaluated by bioimpedance analysis, non to BMI.
Obesity in this pathological picture must considered as a cofactor that give to bisphenol A the possibility to induce a worsening effect on the liver in case of presence of NAFLD, acting as a "lipid reservoir" of bisphenol A. The specific role of bisphenol A in the development of adipose tissue metabolic dysfunction, obesity and NAFLD could be the new field in future scientific literature in hepatology research.
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